INXN-3001

N/A

Report date: 2023/10/26 17:10:49

Base Information

Drug NameINXN-3001
Drug Alias Namehuman IL-12 (hIL-12)-expressing autologous dendritic cellsZIN-CTI-001DC-IL-12IL-12 DNADC-RTS-IL12 +[6] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionGene transferenceInterleukin-12 stimulants
TargetsInterleukin-12
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIntrexon Corporation
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesZiopharm Oncology IncAlaunos Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A